Lisa La on the Next 5 Years in Multiple Myeloma Research

Video

The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.

In an interview with CancerNetwork®, Lisa La, director of clinical research in the Center for Cancer Care at White Plains Hospital, discussed what she hopes will occur in multiple myeloma research over the next 5 years.

Transcription:

Hopefully we find a cure for myeloma. The director that I worked with at Sinai, I remember interviewing someone with him and the coordinator asked him specifically, “What is your goal in myeloma? You’re doing all these things. You've dedicated the last 20, 30 years of your life to myeloma into your patients. Your patients have your cell phone number, they call you at your house.” And he said, “To find a cure, as simple as that, why else would I dedicate my life to myeloma?”

And that resonated with me, you know, and I think that his passion and along with other oncologists that I've met along the way, who have focused on myeloma really, really have a passion and hoping to find a cure. And that's what I hope, that we are one step closer each year, and hopefully in 5 years we would have some sort of cure. But patients are living a lot longer, again, from 10 years ago when I started to now, but you know, we have to keep pushing the boundaries to see what else we can do.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content